Loading…

2SPD-020 Introduction of a new presentation of hyaluronic acid for intra-articular infiltration

Background and importanceIn April 2020, the protocol for the use of intra-articular injections was updated within a multidisciplinary context with Pharmacy, Traumatology and Rehabilitation. Sodium hilauronate 60 mg/4 ml (Hyalone, high molecular weight) was included. According to the new protocol, th...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2022-03, Vol.29 (Suppl 1), p.A9-A10
Main Authors: Sánchez Ruiz, A, Villamizar Tomas, I, Claramunt García, R, Pérez Cano, E, Jiménez López, Y
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importanceIn April 2020, the protocol for the use of intra-articular injections was updated within a multidisciplinary context with Pharmacy, Traumatology and Rehabilitation. Sodium hilauronate 60 mg/4 ml (Hyalone, high molecular weight) was included. According to the new protocol, the use of Adant One (low molecular weight hyaluronic acid) was approved for grades I-II according to the Kellgren–Lawrence index (IKL) or III-IV in cases where Hyalone is not tolerated due to pain. Hyalone was indicated for IKL grades II-III-IV.Aim and objectivesTo evaluate the healthcare and economic impact of the incorporation of a new presentation of hyaluronic acid in the intra-articular infiltration protocol of a regional hospital.Material and methodsRetrospective observational study and economic analysis of drugs used in intra-articular infiltration, comparing a period (period 1) prior to the update of the protocol (April 2019–April 2020), with another period (period 2) 1 year after the implementation of the protocol (April 2020–April 2021). Data were obtained from the electronic prescription program (number of patients, number of dispensations as well as cost per drug and total cost).ResultsThe data obtained are given in Table 1.Abstract 2SPD-020 Table 1 Parameter Period 1 Period 2 Patients (n) 91 94 Adant One (% of patients) 85.10 52.12 Adant (% of patients) 14.89 14.89 Hyalone (% of patients) – 32.97 Adant One cost (€) 5776.53 3367.39 Adant cost (€) 495 363 Hyalone cost (€) – 2803.8 Total costs (€) 6271.53 6534.14 In period 1, the Rehabilitation Service was the service that performed the most infiltrations (52.5% of the total patients treated with Adant One) and 92.85% of the total patients treated with Adant. In period 2, Adant One was used in a similar way. In the case of Hyalone, 96.77% was used by the Rehabilitation Service.Conclusion and relevanceThe introduction of the new presentation of hyaluronic acid allowed a better individualisation of the treatment of intra-articular infiltrations and did not lead to a noticeable cost increase.References and/or acknowledgementsConflict of interestNo conflict of interest
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2022-eahp.19